Loading stock…

Divi's Laboratories Limited (DIVISLAB) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Divi's Laboratories Limited

DIVISLABMarket cap $26BPrice $98.1

Country🇮🇳India

SectorHealthcare

IndustryLife Sciences

Manufactures active pharmaceutical ingredients and intermediates that pharma giants worldwide rely on to make generic and patented drugs. It's one of the largest API producers globally, supplying two of the top three ingredients behind many blockbuster medications.

In Bastion Portfolios?

52W Return+30%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+15%7

Rev CAGR (3y)+19%9

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+23%8

EPS Growth Y+2+22%8

EPS Growth Y+3+22%8

Quality

Margins

EBIT Margin31%9

Net Income Margin26%8

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA-0.810

Efficiency

ROE18%7

ROAna–

Earnings Stability55

GEAR+STRONG80

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)831

P/E Ratio (Forward 3y)521

P/BV15.21

EV Multiples

EV/EBITDA Fwd561

EV/EBIT Fwd631

Yield

Free Cash Flow Yield0.1%3

Dividend Yield0.3%1

Momentum

Short term

1 month return-0%8

3 month return+42%10

YTD return+50%9

Mid term

Price vs 52wHigh97%10

1 year return+57%9

Long term

3 year return+160%9

5 year return+94%7

Risk Shield

Price Risk

Beta0.39

Volatility24%9

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield0.1%3

Quality

ROCE39%10

Earnings Stability55

Net Debt/EBITDA-0.810

02Growth

Is it actually growing, and how fast?

DIVISLABDivi's Laboratories

Revenue FY26$1.1B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+23%8

EPS growth, FY28E+22%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 6%/yr over the last 3 years and is set to grow 19%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 22%/yr vs revenue 19%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

DIVISLABDivi's Laboratories

Total return Current987%

Price return Current919%

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+42%10

YTD return+50%9

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+57%9

3-year return+160%9

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +160% over three years and +94% over five, ahead of 70% of the market.

It's up 57% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+42%) and so far this year (+50%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Divi's Labs. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DIVISLABDivi's Laboratories

Revenue FY26$1.1B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+23%8

EPS growth, FY28E+22%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 6%/yr over the last 3 years and is set to grow 19%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 22%/yr vs revenue 19%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

DIVISLABDivi's Laboratories

Total return Current987%

Price return Current919%

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+42%10

YTD return+50%9

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+57%9

3-year return+160%9

5-year return+94%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +160% over three years and +94% over five, ahead of 70% of the market.

It's up 57% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+42%) and so far this year (+50%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Divi's Labs. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community